Inhaled Mometasone Furoate Improves Health-Related Quality of Life in Patients with Persistent Asthma

Results from two clinical trials of mometasone furoate administered via a dry powder inhaler (MF-DPI) were reviewed to evaluate the consistency of effects of MF-DPI administered once-daily in the evening (QD PM) or twice-daily (BID) on health-related quality of life (HRQOL) in adults with persistent asthma previously treated with inhaled corticosteroids. HRQOL data were collected from two 12-week, randomized, double-blind trials: in study 1 (n = 268), patients received MF-DPI 400 g QD PM (1 inhalation), MF-DPI 200 g BID, or placebo; in study 2 (n = 400), patients received MF-DPI 200 g QD PM, MF-DPI 400 g QD PM (1 inhalation), MF-DPI 200 g BID, MF-DPI 400 g QD PM (2 inhalations of 200 g), or placebo. In both studies, HRQOL was assessed using the Medical Outcomes Survey 36-item Short Form (SF-36) and an asthma-specific module. MF-DPI was associated with consistent, statistically significant improvements in asthma-specific total scores, breathlessness, asthma concerns, and physical symptoms compared with placebo in both trials (p 0.05 vs. placebo). MF-DPI improved SF-36 Physical Component Summary scores at all doses except 200 g QD PM. In conclusion, the results from two placebo-controlled trials suggest that MF-DPI 400 g/d, administered once or twice-daily, produces consistent, statistically, and clinically significant improvement in HRQOL measures in patients with persistent asthma.